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Abstract 
Introduction: The goal of research was to analyze the management of innovative activities 
for innovative medicines market launch in Russia and abroad.  
Materials and methods: In the study there were used methods of cognition, including 
methods of empirical (observation, comparison) and theoretical studies (analysis, 
synthesis, aggregation), scientific assessment, SWOT-analysis.  
Results and discussion: The analysis of domestic and foreign experience in the planning and 
management of research in pharmacology was carried out. Despite the fact that at the present 
time in the Russian Federation a powerful ramified state apparatus for regulating scientific 
research and development in the field of medicine has been formed, the pharmacological 
science remains divided. This leads to a reduction of efficiency of innovative drugs 
development studies. At the same time, in developed countries, interdepartmental coordination 
and advisory bodies (councils, commissions) are active, often at the highest level. This testifies 
to the high attention given in these countries to interdepartmental interaction and intersectoral 
projects in the field of research and development.  
Conclusion: Foreign R & D support systems are characterized by a number of differences 
from domestic mechanisms. A number of recommendations based on the experience of 
foreign colleagues for future measures to modernize existing and introduce new 
mechanisms for state support of research in the field of pharmacology in Russia were 
proposed.  
Keywords: pharmacology, research and development, forecasting, strategic planning 
document, innovative territorial cluster, small and medium-sized enterprise. 
Introduction 
Innovative transformation of the Russian 
economy is a system tool by which the 
government can provide in the long term national 
competitiveness, successfully to solve the 
accumulated problems in the socio-economic 
domain. 
Pharmaceuticals is the most high-tech and 
knowledge-based industry in the world economy 
with research and development rate in total sales 
amount of more than 14%, that in monetary terms 
in 2015 amounted to 150 billion dollars, and in 
2022 it is expected that they will rise to 182 billion 
dollars [1]. 
The effectiveness of investment in research 
and development is confirmed the information 
voiced by the Minister of industry and trade of the 
Russian Federation Manturov D. V., at the 
meeting of the Government Commission for 
import substitution 8 July 2016: "...last year the 
sales volumes of 17 drugs, created with the 
participation of the state, were in 28 times higher 
than their budgetary development cost. Russian 
Rus.  
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drugs also allow to save money and ordinary 
consumers, and the state" [2].  
However, at the present time in Russia there 
is no continuous value chain of an innovative 
product at all stages of its implementation (from 
the research and innovation order to their 
manufacturing application and creation of 
innovative companies). 
As a result, the manufacturing application of 
R & D and commercialization of innovative ideas 
are the exception rather than the rule in the long-
established administration system of innovation 
[3]. 
The President of the Russian Federation V. 
V. Putin in his address to the Federal Assembly in 
2017, said: "...We need to transform research 
projects into successful commercial products; by 
the way, we have always suffered from it, from 
development to implementation the huge time 
goes by... It is true not only of our time, and not 
even the Soviet, and even in the Russian Empire 
everything was the same. We need to reverse this 
trend – we can do it..." [3].  
In this regard, the stated goal of the study the 
management of innovation in bringing to market 
innovative drugs in Russia and abroad is relevant 
and will help to formulate recommendations on 
future actions for the modernization of existing 
and introduction of the new mechanisms of state 
support of scientific research in the field of 
pharmaceuticals in the Russian Federation. 
Materials and methods 
In the study there were used the methods of 
cognition, including methods of empirical 
(observation, comparison) and theoretical studies 
(analysis, synthesis, aggregation), scientific 
assessment, SWOT-analysis. Each of these 
methods is applied adequately on the 
functionality. Targeted application of these 
methods ensured the reliability of the estimates 
and conclusions obtained in the study. 
The study subject was the state policy in the 
field of strategic planning in the Russian 
Federation, and in economically developed 
countries. Matrix regulation of state strategic 
planning in the Russian Federation in the field of 
pharmaceutics unifying key concepts: 
forecasting, goal setting and planning is presented 
in figure 1. 
From the matrix it follows that the President 
of the Russian Federation and the government of 
the Russian Federation determine the goals, 
objectives and priorities strategic planning and 
the Federal Executive authorities carry out a 
direct development of the strategic planning 
documents, monitoring and control of their 
implementation. However, a promotion of 
coherence, balance and agreement of the strategic 
planning documents and determination of 
sequence of their development are a function of 
the Government of the Russian Federation. 
With the aim of developing 
recommendations and new mechanisms for more 
effective management in the field of 
pharmaceutical science it was necessary to study 
the experience of foreign countries. 
Results and discussion 
The analysis of activity of Federal Executive 
authorities of the Russian Federation for the 
planning and management of research in the field 
of pharmaceuticals 
It is obvious that research and development 
in pharmaceuticals are becoming more difficult to 
separate from other fields of science, and as a 
result, inter-industry and/or interdisciplinary 
projects take on greater and greater economic and 
social importance. A number of sectoral strategies 
(the Strategy for medications supply to the 
population of the Russian Federation for the 
period until 2025, the development Strategy of the 
pharmaceutical industry of the Russian 
Federation for the period until 2020) approved at 
the departmental level, which cannot be 
conducive to effective cooperation between the 
interested public authorities [5, 6]. 
At the same time, it is necessary to create a 
unified system of priorities and research planning, 
which will allow to eliminate duplication of 
scientific topics, to concentrate available financial 
and other resources in the most "critical" points, 
not to break the innovation chain and to 
coordinate all its stages from research to 
implementation. 
Strategic planning documents have 
repeatedly emphasized the importance of 
organization priority lines of development of 
science and technology. 
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Fig. 1. The matrix of strategic planning in the Russian Federation in the field of pharmaceuticals 
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In accordance with the decree of the 
President of the Russian Federation of 07.07.2011 
No. 899 "Life sciences" related to priority lines of 
development of science, technology and 
engineering in Russia. The list of critical 
technologies of the Russian Federation included 
biomedical technology, genomics, proteome, 
post-genomic, cellular technologies, technologies 
of loss enhancement from socially significant 
diseases, which are direct products of scientific 
research and development in pharmaceutics. 
However, the question arises, how narrow 
should be the line and to what extent should 
specify the priorities of the state in the field of 
science. 
The decree of the President of the Russian 
Federation of 01.12.2016 No. 642 adopted the 
Strategy for scientific and technological 
development of the Russian Federation, which 
envisages the transformation of science and 
technology in a key factor of the development of 
Russia and ensure the country's ability to respond 
effectively to big challenges1. 
One of the most important from the point of 
view of scientific and technological development 
of the Russian Federation the great challenge is 
"...rising threat of global pandemics, increasing 
the risk of new and return of extinct infections." 
In the Strategy of scientific and technological 
development of the Russian Federation there are 
stated that, in the next 10 to 15 years, the priorities 
of scientific and technological development of the 
Russian Federation should be considered to be 
those areas that will allow to obtain scientific and 
technical results and to create technologies which 
are the basis for innovative development of the 
domestic market of products and services, a stable 
position of Russia on the foreign markets, and 
provide, including "the transition to personalized 
medicine, high-tech health care, and technology 
of health care, including through the rational 
administration of drugs (especially 
antibacterial)".Financial support for the 
implementation of that Strategy effected on 
account of federal budget allocations, including 
those allocated for realization of state programs of 
the Russian Federation. 
In the approved state programs of the Russian 
Federation concerning the development of 
pharmaceutical science ("Health Development", 
"Development of pharmaceutical and medical 
industry" for 2013-2020, "Development of 
science and technologies" for 2013-2020) there is 
a pronounced emphasis on the technological 
aspect of production, market development, 
improving the competitiveness of domestic 
products. In addition, a lot of attention from the 
state is paid to the effective implementation of the 
results of scientific research and development in 
industry, their commercialization and the 
development of mechanisms of state-private 
partnership [7, 8, 9]. 
In addition, when comparing the activities of 
these state programs, there is a high proportion of 
inter-sectoral activities requiring effective 
interagency cooperation. 
Analysis of indicators of efficiency of 
realization of the state programs of the Russian 
Federation allows to highlight 4 of the most used 
groups of indicators: 
indicators of publication activity; 
indicators of scientific and innovative 
activity; 
the indicators characterizing financial and 
economic efficiency of implemented actions; 
indicators of changes of scientific and 
innovative infrastructure. 
However, at the present stage of development 
of the span of control of scientific research and 
development, it seems advisable to move to more 
complex relative indicators that will characterize 
the efficiency performance of R & D and their 
practical significance. 
For example, to the present day the 
demographic indicators and the indicators 
characterizing the health status of the population 
are not used as indicators of the effectiveness of 
the implementation of measures for development 
of pharmaceutical science. Also, such indicators 
could serve indexes of the effectiveness of 
individual methods of diagnosis and treatment. 
Thus, there is a flagrant necessity for a 
substantial modification and improvement of the 
system of indicators of efficiency of realization of 
measures on development of scientific researches 
and developments area in the field of 
pharmaceuticals. The reason for this is not only a 
need to gather more informative performance 
indicators, but also the insufficiency of basic data 
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for planning of concrete lines of development of 
the pharmaceutical science. 
Reviewing strategic documents stem from a 
common understanding of the key systemic 
problems prevailing in many knowledge-
intensive industries of Russia's economy. These 
issues include: 
technological backwardness and product 
obsolescence caused by a development gap of 
industries, infrastructure and markets; 
dissociation of participants of innovative 
activity caused by the lack of development of the 
environment within the country; 
fragile integration in international markets, 
caused by low competitiveness. 
These problems mutually cause each other 
and have their own peculiarities in every industry, 
but most of the objectives formulated in the 
strategies aimed at overcoming these problems. 
For general characteristics of the system of 
strategic documents it should be noted that their 
developers among the possible approaches to the 
regulation of innovative activity chose a 
combined strategy based on coordination of 
efforts of the state, large corporations, research 
organizations and market insiders, a high value set 
on attracting international participants. 
In the development scenarios of industries 
there is also commonality. The initial stages of the 
strategies implementation give pride of place to 
creating a stimulating innovation, information 
and analytical infrastructure, reforming the 
system of scientific organizations. Further stages 
of integration are meant to be integrative when 
systemic effect from the provided resources and 
infrastructure, organized and stimulated 
interactions between process actors begins to 
appear. In other words, the initial stages can be 
characterized as an investment, and subsequent 
stages are as innovative. 
All documents separately consider a problem 
of staffing system of training, retraining and 
retention of personnel. Given problem is 
accentuated by the gap between generations of 
professionals. The decision of the personnel 
problem lies in the interaction of the most 
competitive educational institutions and scientific 
organizations and enterprises, as well as through 
invitation of high-level specialists from abroad. 
An obligatory element of these strategies is 
the use of a model of scientific-educational-
industrial clusters as groups of enterprises, 
suppliers of equipment and components, 
specialized production and services, research and 
educational organizations, linked by relations of 
territorial proximity and functional dependence in 
the production and sale of goods and services. It 
provides for the formation and promoting the 
activities of a few dozens of these associations in 
different regions of the Russian Federation. 
So, now the following innovative territorial 
clusters in the field of pharmaceuticals created 
and developed: 
Biotechnological innovation territorial 
cluster Pushchino; 
Kaluga pharmaceutical cluster; 
Cluster "Phystech XXI" (Dolgoprudny); 
The cluster of medical and ecological 
instrument engineering and biotechnologies of St. 
Petersburg; 
Altai biopharmaceutical cluster 
"ALTAIBIO"; 
Pharmaceutics, medical equipment and 
information technology of Tomsk region; 
Innovative cluster of information and 
biopharmaceutical technologies of Novosibirsk 
region. 
Similar approaches are used in management 
strategies. To coordinate the efforts of the 
implementing strategies there are created 
interagency councils, funds of an intellectual 
property, expert board. 
Based on the above information and 
documents we can conclude that in the Russian 
Federation an extensive system of state regulation 
of the scientific researches and developments area 
in the field of pharmaceuticals has formed. The 
most influential actors in this process are the 
Ministry of education and science of the Russian 
Federation, the Ministry of health of the Russian 
Federation and the Ministry of industry and trade 
of the Russian Federation. 
However, other Federal Executive authorities 
also appropriate significant budget funds for 
research and development for further application 
of their results in the field of health, including 
those ministries and agencies that do not have real 
powers in the development of pharmaceutical 
science. 
Thus, despite the fact that currently in the 
Russian Federation an extensive state apparatus 
for the regulation of scientific research and 
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development in medicine has formed, 
pharmaceutical science remains fragmented. One-
level activities and work can be carried out in 
institutions of the Ministry of health of Russia 
(including the Federal Medical and Biological 
Agency of Russia and Federal Service for 
Supervision in Healthcare), and Ministry of 
education and science, Ministry of industry and 
trade, Federal Agency for Scientific 
Organizations of Russia, whose activities in the 
field of pharmaceutical research is not 
coordinated. It leads to a reduction of the 
efficiency of research works in the field of 
pharmaceuticals. 
The creation of a supra-departmental agency 
for the most effective regulation of scientific 
research and development in the field of 
pharmaceuticals and ensure the necessary level of 
coordination is obvious. 
It emerges full blown in connection with a 
simultaneous increase in the Russian Federation 
the number and significance of intersectoral 
and/or interdisciplinary research and 
development projects in the field of 
pharmaceuticals. 
The analysis of the foreign experience of 
planning and managing scientific research in the 
field of medicine 
Even with the recognition of the high 
importance of development of science and 
innovation for social and economic welfare of the 
country and national security, no state may 
conduct scientific research and development at a 
modern level in the all lines. In this regard, it is 
necessary to select priority lines to focus the main 
efforts of the government and where funds should 
be invested primarily. 
Thus, the most important task of science 
policy is to develop tools for identifying scientific 
and technological priorities, and mechanisms for 
their implementation. 
In the course of analysis of experience in 
application a systematic approach in forecasting 
research activities in the field of medicine in 
foreign countries at the state level there was 
found: 
relevant agencies determine, in the first place, 
the priority lines of development of health in 
general, in some cases, the list of the priority lines 
of development of medical science was compiled, 
but the principles and methodology of formation 
of the specified lists in the official resources are 
not given; 
the circle of "critical technologies" for 
medical science identified through a 
comprehensive study on formation of the list of 
critical technologies at the state level; 
the most progressive at the moment 
forecasting method "foresight" is also used to 
determine the priority lines of development of 
medical science in integrated studies. 
The choice as a priority line the 
pharmaceutical science, in one degree or another, 
reflected in scientific and technical policy of such 
countries as the USA, the UK, France, Japan, 
Germany and Finland. 
In these foreign countries (except the USA), 
in the structure of Federal Executive authorities 
there is defined the agency responsible for the 
integrated development of science and innovation 
in the country. And not always the relevant 
agency plays a significant role in the regulation of 
scientific research and development in the field of 
medicine. Fundamental researches is usually 
planned and financed by the agency responsible 
for scientific and technical state policy 
implementation. 
The tasks of ensuring the interaction of 
science and industry, successful 
commercialization of scientific development and 
the coordination of industrial R & D in general, as 
a rule, are also provided by the agency responsible 
for scientific and technical state policy 
implementation, or organizations, subordinated to 
it. The presence in developed countries, special 
institutions (agencies) responsible for 
commercialization of scientific developments and 
technology transfer reflects the recognition of the 
special importance of these tasks for the interests 
of the state. 
In all listed above countries the interagency 
coordination and consultative organizations 
(councils, commissions) actively operate, often at 
the highest level. It testifies to the high attention 
in developed countries, interagency cooperation 
and joint industry projects in the field of scientific 
research and development. 
The allocation of the funds on priority lines 
of the science and technology development, as a 
rule, is through special state funds. 
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The foreign R & D support systems are 
characterized by a number of differences from the 
domestic mechanisms: 
the implementation of the personal grant 
support of specialists in various fields to support 
the research of young people from college to 
heads of laboratories; 
a presence in many countries of Europe, 
BRICS, the USA, in addition to the general 
natural-science funds and support programs, 
specialized funds for specific fields of science 
(e.g., biological, biomedical researches, etc.); 
wider involvement of "corporate" science to 
the solution of public problems and coordination 
of the efforts with the University and Federal 
science. 
A possible solution of a number of the 
scientific tasks in the field of pharmaceuticals, 
could be the introduction in Russia of the 
financing instruments of the international 
scientific consortia.  
So, in the USA there is a few years of 
successfully operating a support program for 
internal research teams from the EU countries. 
The EU, in turn, through the Horizon 2020 
program actively involves in-house development 
of participants from around the world. 
All European funding for Russian scientists 
since 2014 amounted to 1.38 million euros (in this 
case, funds are mainly personal grants, for 
example, as part of the MSCA (Marie-
Sklodowska-Curie Action)). 
It should be noted that the analysis of 
instruments of international cooperation, Western 
partners have allocated considerable funds for the 
promotion of the private science, research and 
policy. For example, Partnership Instrument 2015 
Annual Action Programme covered by the 2014-
2017 Multi-annual Indicative Programme intend 
specifically related to "public diplomacy". 
Planned within the program activities fit into 
the strategy of the public diplomacy of the EU, 
which covers four areas: work with the scientific 
community; joint policy research and discussions 
having a mutual interest; cooperation with 
representatives of civil society on issues of 
common interest, using culture as a vector for the 
public diplomacy. Grants as a part of one of the 
program sections (the "EU Policy and explanatory 
partnership" – "Cultural diplomacy") apply to 
Russia, Japan, China, the USA, Central America, 
South America, the Asia-Pacific region with a 
budget of 15.5 million euros. 
However, one of the major goals of state 
regulation in the area of scientific research and 
development, including in the field of the 
medicine, is to encourage the continuous transfer 
of knowledge and technology from science to the 
economy, because the market independently, 
without special incentives, is unable to provide 
the necessary economic development level of 
funding for science. 
In developed countries, there was 
accumulated a vast experience in the integration 
of research results into practice industries. In this 
aspect, the involvement of the private sector plays 
an important role, as the volume of the budget of 
any state is limited. The analysis of foreign 
experience revealed common mechanisms for 
attracting commercial organizations for financing 
of scientific activities, namely: 
1) Economical motivation for research
cooperation in the private sector and research 
cooperation of the private sector with the state and 
university sectors, including tax incentives of the 
cooperation, concessional lending of the common 
projects, cost sharing major science and 
technology projects by the state. 
It should be noted that if before the tax 
benefits acted only in respect of companies 
conducting research and development on their 
own, currently in most countries these benefits 
apply to companies conducting research and 
development by outsourcing. 
Of course, tax benefits are not considered by 
governments of developed countries as the only 
effective method of stimulation of the research 
and innovation, but they have some advantages, 
for example, in comparison with government 
programs providing subsidies or grants. 
In particular, tax incentives do not reduce the 
autonomy of companies in relation to the state, in 
contrast to programs providing subsidies or 
grants, realizing which the state retains significant 
control functions. Therefore, when choosing of 
research areas, the companies in this case follow 
by real market needs and not demand from the 
state. In addition, tax incentives require less 
paperwork, that facilitates the operation and the 
companies themselves, and government bodies 
[10]. 
Semin A.A. State support for research in pharmacology: an analysis of foreign and domestic 
experience. Research result: pharmacology and clinical pharmacology. 2017;3(3):157-168. 164 
September. 2017. 3(3). Res Result Pharmacol Clin Pharmacol. rrpharmacology.ru 
In the USA there are over hundreds of 
benefits which are got not an advance but as an 
incentive for real activity. The main difference 
between the Western system benefits from the 
Russian is that they are provided not scientific 
organizations, but investors. Thus regular review 
of benefits allows the government to purposefully 
stimulate innovation in priority sectors, to 
influence the strength and structure of scientific 
and innovation organizations [11]. 
However, direct financing of research and 
development from the state budget remains the 
main economic instrument of the state scientific 
and technical policy. In developed countries the 
share of public funding can reach 40% of national 
research expenditures. In addition, for basic 
research, it is much higher: from 50 to 70% in 
different countries [10]. 
2) Donation or grant on preferential terms in
the permanent or temporary use of state property 
for conducting research and development to 
private sector companies.  
One of the main forms of transfer of Federal 
property for temporary use to private companies 
in the US is the agreements on joint research and 
development. The company conducts research on 
the subject, given by the Federal Agencies.  
Also in developed countries there is used the 
organization of common use centers (CUC), 
which allows companies to use equipment to 
conduct research (on a paid basis or free of 
charge). This mechanism is an effective incentive 
for companies with high research potential, but 
lack of funds to purchase expensive equipment. 
When using the equipment of the CUC, the 
organization determines its own theme 
independently, the problem is only that whether 
the CUC with the necessary equipment. 
3) Creation of demand from the state to the
results of research and development through the 
mechanisms of a state order. 
In fact, government procurement of the high-
tech products is the creation of a new market for 
domestic manufacturers.  
Example of practical implementation of this 
mechanism is launched in 2004 in the USA, the 
project "Biological shield" under which the state 
guarantees the demand for vaccines and 
medicines of new generation, able to protect 
Americans from threats of bioterrorism. The 
project assumed that within 10 years, the 
Department of homeland security will spend of 
$5.6 billion for the purchase of anti-anthrax, 
smallpox and other biological and chemical 
poisons [12]. 
However, without in-depth development of 
the issue the public procurement can easily 
become inefficient spending of the budget funds. 
It is true both for the procurement mechanisms 
and mechanisms for the selection of objects for 
purchase. It is obvious that even the most 
prosperous state is not able to procure the entire 
range of the high-tech products (even very 
promising), produced in the country. First of all, 
an attention should be paid to the departments, 
products purchase of that simultaneously 
contributes to solving other national problems (in 
particular, enhancing the country's defense, 
improve the health of the nation, etc.). 
4) The development of public-private
partnership. 
In many countries of the Organization for 
Economic Co-operation and Development 
(OECD), the share of state budget allocated 
through public-private partnership (PPP) is 
constantly growing [13]. For example, in 
Germany the PPP programme in the research field 
began to be implemented back in the 1970-ies, so 
the share of the public funding of R & D has 
currently dropped from 70 to 30% [14]. 
It should be noted that the instrument of PPP 
can be seen not only as a way of dividing the costs 
of implementation of any initiatives in research 
and innovation area, but also as a method of 
regulating relations between subjects of scientific 
and innovative activities. In most developed 
countries, PPPs are used as co-financing, and 
regulation. As a tool of co-financing PPP prevails 
in most the EU countries, but as an instrument of 
regulation it is in the United States and Japan [15]. 
The most common forms of PPP are co-
financing of research projects on pre-competitive 
stage (and then the incentive for industry 
participation is the transfer of rights to the results 
of research and development for their further 
commercialization); co-financing of the early 
stages of commercialization ("seed", venture 
financing); organization of joint research centers 
in the areas that are traditionally in the state area 
of responsibility (including health service); 
acceleration of the development of technical 
standards necessary to regulate research and 
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innovation activities, the development of clusters 
and innovation infrastructure, support of small 
innovative enterprises and stimulate the creation 
of new small firms. 
5) The creation and support of technology
platforms 
Under the "Seventh framework programme 
for the development of scientific research and 
technological development" (FP7), which served 
as the main instrument of the EU to support 
scientific research and development and to attract 
private financing in the period from 2007 to 2013, 
there were established the European Technology 
Platform (ETP). 
Through the work of the ETP, the 
representatives of European industry, universities 
and research institutions affect the policy of the 
European Commission in the field of science and 
technology. In particular, the topics of the 
research unit of Cooperation in the last FP7 
program were formed on the basis of programs of 
strategic researches of the technological 
platforms. It ensures a relevance for the industry 
of sponsored research topics. 
6) The use of potential of small firms as
sources of innovation 
Initiatives in relation to small and medium 
innovative entrepreneurship are realized in most 
developed countries. Sufficiently developed 
forms of such support are in the USA, the UK, 
France, Germany, Finland. 
Various schemes and programmes of state 
support for entrepreneurship, especially 
innovative, are formed taking into account 
dynamics of development of the respective 
projects and the level of their private investments. 
The typical model of development of innovative 
project and its financial support is presented in 
figure 2. 
Fig. 2. Scheme of financial support for innovative projects by the EU and individual EU members 
Herewith they use various mechanisms, 
including financial support in various forms, 
activities in the field of training and retraining of 
specialists, access to information, technology and 
markets, provision of tax preferences, such as the 
benefits for small firms or tax credit for investors, 
funding a small business [16]. 
In the United States to encourage the 
cooperation between state organizations and the 
private sector there was enacted a law on 
cooperative research and development between 
Federal research institutions and commercial 
companies [17]. The law provided access to all 
interested USA companies to the scientific and 
technical resources of the Federal laboratories at 
the account of restrictions related to national 
security. In this case we are talking about research 
and development, customer of that is the Federal 
Executive authority and that was reckoned on an 
achievement of results that have a commercial 
value. The Federal laboratories are permitted to 
transfer the rights of ownership of the results of 
scientific and technological activities to the 
private enterprise. Small and medium-sized 
innovative firms are granted advantages in the 
form of exclusive licenses. 
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Another example is the support program for 
cooperative research centers operated by the 
National Science Foundation of the United States. 
The cooperative research centers are the pools, 
concentrated around the universities and 
involving at least six partners from industry. They 
are to promote the results of research conducted 
in the universities or the government laboratories, 
to industry. 
Also the most well-known, having more than 
30 years of history, and therefore well-studied the 
US programs: Small Business Innovation Research 
and Small Business Technology Transfer can be the 
example of a mechanism to provide financial 
assistance for the development of small innovative 
enterprises [18].  
Innovative research program in the small 
enterprise has become a kind of model for other 
countries, which also began to support small 
innovative entrepreneurship as an important 
component of the national innovation system. It is 
meant to be start-up capital for the small 
enterprise and help them to participate in R & D 
funded by the government. 
In the EU within the program Horizon 2020 
for the first time there is being implemented the 
initiative (program) aimed at creating a special 
system of state co-financing and other forms of 
support for the innovative micro, small and 
medium enterprises. This program is called 
Horizon's 2020 SME Instrument – SMEI [19]. 
The SMEI program has a solid budget, which is 
about 3 billion euros for the period 2014-2020, 
that is slightly less than 30% of the amount 
allocated within the Horizon 2020 program on the 
research and development of the small and 
medium-sized enterprises [20]. 
SMEI largely copies successfully used in the 
USA Small Business Innovation Research and 
Small Business Technology Transfer programs. 
SMEI unlike other programs allows for the 
possibility to be a member of one private small 
and medium enterprise (SME), while other 
similar programs require that the innovative 
project was implemented by a consortium of two, 
three or more partners. 
Also, from January 2015 within the Horizon 
2020 program a new SME support program “Fast 
Track to Innovation pilot – FTI” has started in a 
pilot mode [21]. In the EU appeared first program 
aimed at the direct financial support of the 
innovative projects in advanced stages that 
precedes the entry of innovations into market, i.e. 
their commercialization. This period corresponds 
to technology readiness levels TRL 6 – TRL 9. 
Also the experience of support for small 
firms in France by the National Agency for 
improving the innovative attractiveness of 
scientific research (ANVAR) is of some interest. 
The Agency has the industrial and commercial 
status and operates as an independent concern, but 
its mission is defined by the government, and it 
also provides the essential tools [22].  
The Agency may provide interest-free loans 
for up to 5-6 years, covering up to 50% of the total 
costs associated with the implementation of the 
innovative project or a project on technology 
transfer which are repayable in case of successful 
completion of the project. In addition, grant-
making is possible for the preparation and 
completion of innovative programs, floating 
innovative companies, increasing the 
technological level of small and medium-sized 
enterprises (through the involvement of 
researchers, formulation and use of scientific and 
technical information, etc.), as well as 
encouraging greater participation by small and 
medium-sized enterprises in the European 
projects of a technological cooperation. 
Figure 3 shows the three sources for financial 
support to SMEs in the EU, which operate 
through financial intermediaries, using a wide 
range of instruments: loans; guarantee for loans; 
counter-guarantees; mezzanine financing, or, as it 
is called bridge financing; venture capital 
investments; joint-stock investment etc. 
Semin A.A. State support for research in pharmacology: an analysis of foreign and domestic 
experience. Research result: pharmacology and clinical pharmacology. 2017;3(3):157-168. 167 
September. 2017. 3(3). Res Result Pharmacol Clin Pharmacol. rrpharmacology.ru 
Fig. 3. Scheme of financial support for SMEs and larger companies by the EU and individual EU 
members 
The EU supports entrepreneurship through 
numerous financial institutions on the ground. 
Such institutions throughout the EU there are 
more than 1 thousand Annually, support is 
provided to over 200 thousand enterprises of 
different size and degree of development, since 
the starting and ending expanding enterprises 
[23]. It is important that the EU aims to make 
financial support to SMEs the most convenient 
and quickly. In particular, there was created a 
specialized portal that makes it easy to find the 
appropriate financial institution in any EU 
country. 
Thus, based on the experience of foreign 
colleagues, we can outline a number of 
recommendations regarding future measures on 
modernization of existing and introduction of new 
mechanisms of state support of scientific research 
in the field of pharmaceutics: 
the development of narrow strategic 
development plans of specific areas of the 
science; 
support of certain direction projects included 
in the development strategy of the priority 
industries; 
creation of the specialized fund of the 
projects focused support in the field of 
pharmaceuticals. 
orientation of activities aimed at international 
cooperation in the field of pharmaceuticals, on the 
advanced countries for specific scientific tasks 
(creation of new lines) and neighboring countries 
(developing and maintaining a well-established 
cooperatives); 
development and adoption of measures 
aimed at popularization of the Russian science 
(support popular science publications, 
conferences and exhibitions for pupils and 
students, etc.); 
individual support of young scientists within 
the science organizations, designed to stimulate 
the development of domestic competencies. 
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